Bristol Myers Shells Out $4.1B for Turning Point’s Targeted Cancer Drugs

Turning Point Therapeutics is being purchased by biopharmaceutical heavyweight Bristol Myers Squibb, and the $4.1 billion deal will give the latter access to the experimental cancer drug Repotrectinib. Based on the deal’s hefty price tag, BMS sees Turning Point as being worth around $76 per share...